Detalhe da pesquisa
1.
Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments.
JAMA
; 331(19): 1646-1654, 2024 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648042
2.
Pivotal Trial Demographic Representation and Clinical Development Times for Oncology Therapeutics.
JAMA
; 330(24): 2392-2394, 2023 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38079163
3.
The Opioid Industry Documents Archive: A Living Digital Repository.
Am J Public Health
; 112(8): 1126-1129, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35830677
4.
Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study.
BMJ Med
; 3(1): e000802, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38596814
5.
Published research on the human health implications of climate change between 2012 and 2021: cross sectional study.
BMJ Med
; 3(1): e000627, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38352020
6.
Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a cross-sectional study.
BMJ Open
; 13(1): e069115, 2023 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36690402
7.
Characterization of US Food and Drug Administration Class I Recalls from 2018 to 2022 for Moderate- and High-Risk Medical Devices: A Cross-Sectional Study.
Med Devices (Auckl)
; 16: 111-122, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37229515
8.
eHealth technologies assisting in identifying potential adverse interactions with complementary and alternative medicine (CAM) or standalone CAM adverse events or side effects: a scoping review.
BMC Complement Med Ther
; 20(1): 239, 2020 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32727531
9.
Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.
JAMA Netw Open
; 7(5): e249233, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691363
10.
Availability of Unique Device Identifiers for Class I Medical Device Recalls From 2018 to 2022.
JAMA Intern Med
; 183(7): 735-737, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37184854
11.
Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics.
JAMA Netw Open
; 6(8): e2331753, 2023 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37651145
12.
Medical device risk (re)classification: lessons from the FDA's 515 Program Initiative.
BMJ Surg Interv Health Technol
; 5(1): e000186, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38033980